Want to see SE:SYNACT full AI Analyst Report?
SYNACT Stock Chart & Stats
kr19.44
-kr0.02(-0.11%)
At close: 4:00 PM EDT
kr19.44
-kr0.02(-0.11%)
Day’s Range― - ―
52-Week Rangekr7.05 - kr25.30
Previous CloseN/A
Volume64.35K
Average Volume (3M)194.48K
Market Cap
kr992.74M
Enterprise Valuekr1.17K
Total Cash (Recent Filing)kr14.23M
Total Debt (Recent Filing)kr929.00K
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding56,213,966
10 Day Avg. Volume106,126
30 Day Avg. Volume194,483
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageThe exceptionally low debt burden limits interest and refinancing pressure, preserving financial flexibility while SynAct advances its pipeline. A relatively strong equity base also provides more capacity to fund development than a highly leveraged balance sheet would allow.
Focused Differentiated PipelineA focused lead program and differentiated therapeutic objective give SynAct a clear development strategy rather than a broad, unfocused portfolio. Oral delivery and inflammation resolution could support clinical utility if trials validate the proposed approach.
Losses Improved Versus 2023The reduction in losses from the 2023 level indicates that expenditure and development performance can improve meaningfully over time. While the later deterioration makes the trend uneven, the historical improvement offers evidence of potential cost-control leverage.
Bears Say
No Commercial RevenueWithout recurring product revenue, SynAct has no established commercial engine to fund research and development internally. Future value therefore depends heavily on clinical progress and eventual partnering or commercialization of resomelagon.
Sustained Cash BurnPersistent operating and free-cash-flow deficits require SynAct to keep financing development externally while its pipeline remains pre-commercial. Continued burn can reduce financial flexibility and create dilution risk if additional capital is needed.
Heavy And Uneven LossesLarge recurring losses show that SynAct has not yet converted research investment into earnings or operating leverage. The renewed deterioration after earlier improvement suggests cost trends remain volatile, increasing uncertainty around the path to profitability.
SynAct Pharma AB News
SYNACT FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was kr7.05 and its highest was kr25.30 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is kr992.74M.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Nov 03, 2026 which is in 32 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on Aug 20, 2026. The company reported -kr0.392 earnings per share for the quarter.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 56,213,966 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -kr0.392 in its last earnings report. Following the earnings report the stock price went down -9.93%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in SE:SYNACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
InDex Pharmaceuticals Holding AB
―
Active Biotech AB
―
Cantargia AB
―